Status: Recruiting
A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
This integrated Ph1/2 clinical study is to assess the safety, tolerability and pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of OCT-980 in healthy volunteers and participants with RHO-adRP.
Participants needed: 18
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Octant, Inc.Updated: Sep 24, 2026Locations: 2
Eligibility criteria
Participants must have a diagnosis of Rhodopsin-associated, autosomal dominant R... [+10]